Ascelia Pharma: All attention on the top priority - Redeye

Ascelias priority is to secure a re-reader evaluation of SPARKLE by May 2024. This involves minimising the risk of eccessive intra reader variability. The time table is realistic but the risk for delays are never zero. Our base case in now a US partner strategy which could bring several advantages in our view. Our update includes a base case valuation of SEK 10 (11) and a Bull Case of SEK 26 (28), and a Bear Case of SEK 3 (3).

Länk till analysen i sin helhet: https://www.redeye.se/research/942863/ascelia-pharma-all-attention-on-the-top-priority?utm_source=finwire&utm_medium=RSS